ARS Pharmaceuticals, Inc. Common Stock (SPRY) is a publicly traded Healthcare sector company. As of May 20, 2026, SPRY trades at $7.83 with a market cap of $724.91M and a P/E ratio of -3.83. SPRY moved +8.65% today. Year to date, SPRY is -28.90%; over the trailing twelve months it is -45.57%. Its 52-week range spans $6.66 to $18.90. Analyst consensus is strong buy with an average price target of $27.50. Rallies surfaces SPRY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ARS Pharmaceuticals to Remove CVS Prior Authorizations by July 1 Following 3x Neffy Volume Surge: ARS Pharmaceuticals expects to secure CVS Caremark coverage and remove prior authorizations by July 1, aligned with marketing initiatives for a back-to-school surge. The company tripled neffy prescription volumes year-over-year and more than doubled revenue, with 28,000 physicians prescribing and expansion into lower decile accounts underway.
| Metric | Value |
|---|---|
| Price | $7.83 |
| Market Cap | $724.91M |
| P/E Ratio | -3.83 |
| EPS | $-2.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.90 |
| 52-Week Low | $6.66 |
| Volume | 1.40M |
| Avg Volume | 0 |
| Revenue (TTM) | $98.99M |
| Net Income | $-197.98M |
| Gross Margin | 0.00% |
3 analysts cover SPRY: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.50.